Cyclacel Pharmaceuticals Inc
CYCCP
Company Profile
Business description
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.
Contact
Sector
Healthcare
Stock type
Industry
Biotechnology
Fiscal Year End
Employees
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,416.60 | 57.70 | -0.68% |
CAC 40 | 7,541.36 | 63.58 | 0.85% |
DAX 40 | 19,120.93 | 105.52 | 0.55% |
Dow JONES (US) | 42,352.75 | 341.16 | 0.81% |
FTSE 100 | 8,280.63 | 1.89 | -0.02% |
HKSE | 22,736.87 | 623.36 | 2.82% |
NASDAQ | 18,137.85 | 219.37 | 1.22% |
Nikkei 225 | 38,635.62 | 83.56 | 0.22% |
NZX 50 Index | 12,619.94 | 47.28 | 0.38% |
S&P 500 | 5,751.07 | 51.13 | 0.90% |
S&P/ASX 200 | 8,150.00 | 55.20 | -0.67% |
SSE Composite Index | 3,336.50 | 248.97 | 8.06% |